Medical Xpress

Clinical guideline for moderate-to-severe ulcerative colitis released

The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published in Gastroenterology. This ...
clinicaladvisor.com

Standardized Definition of Mild to Moderate Ulcerative Colitis Needed

ulcerative colitis, inflammatory bowel disease, IBD, UC Researchers performed a systematic review of clinical trials to assess the need for a consensus on the definition of mild to moderate, active ...
Nasdaq

Bristol Myers Squibb Announces Positive Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Patients with Moderate to Severe Ulcerative Colitis

Zeposia is the first oral sphingosine-1-phosphate (S1P) receptor modulator to demonstrate benefit in moderate to severe ulcerative colitis in a Phase 3 study PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol ...

Spyre says bowel disease drug cuts inflammation in mid-stage trial

June 15 (Reuters) - Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal of significantly reducing disease severity in a mid-stage trial. Here are some details: • ...
Healio

Skyrizi snags FDA approval for moderate to severe UC; first IL-23 approved for UC, CD

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
clinicaladvisor.com

American Gastroenterological Association Releases First “Living” Guideline for Moderate-to-Severe Ulcerative Colitis

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Business Wire

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
MedPage Today

Etrasimod Shows Promise in Moderate to Severe Ulcerative Colitis

Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, led to clinically meaningful improvements in patients with moderately to severely active ulcerative colitis ...
Morningstar

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...
Healio

FDA approves Zeposia for moderate-to-severe ulcerative colitis

Please provide your email address to receive an email when new articles are posted on . Zeposia (Ozanimod, Bristol Myers Squibb), the first sphingosine 1-phosphate (S1P) receptor modulator approved ...

ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial — Rare Cancer Concerns Hit Sentiment

The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment.